A5044005554- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal disorders and treatments
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related Molecular Pathways
- Metastasis and carcinoma case studies
- Renal cell carcinoma treatment
- Ocular Oncology and Treatments
- Genetic factors in colorectal cancer
- Glaucoma and retinal disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Clinical Nutrition and Gastroenterology
- Glycosylation and Glycoproteins Research
- Neurofibromatosis and Schwannoma Cases
- Autoimmune Neurological Disorders and Treatments
Hôpital Bichat-Claude-Bernard
2014-2024
Assistance Publique – Hôpitaux de Paris
2008-2024
Université Paris Cité
2009-2024
Centre Hospitalier Universitaire de Nice
2023
Hôpital Pasteur
2023
Université Côte d'Azur
2023
Université Claude Bernard Lyon 1
2015-2021
Délégation Paris 7
2010-2019
Inserm
2006-2010
Sorbonne Université
2010
Temozolomide (TEM) showed encouraging results in well-differentiated pancreatic neuroendocrine tumors (WDPNETs). Low O 6 -methylguanine-DNA methyltransferase (MGMT) expression and MGMT promoter methylation within correlate with a better outcome under TEM-based chemotherapy glioblastoma. We aimed to assess whether could help predict the efficacy of patients WDPNET. Consecutive progressive WDPNET and/or liver involvement over 50% who received TEM between 2006 2012 were retrospectively studied....
Abstract Purpose: Gastrointestinal stromal tumors (GIST) are frequently associated with gain-of-function mutations of KIT, which can be inhibited by imatinib both in vitro and vivo. The survival patients GIST, following therapy, has been correlated the nature but not KIT expression. Experimental Design: Subcellular localization, activation, trafficking mature immature forms were investigated GIST samples NIH3T3 cells infected two different GIST-type exon 11–mutated human cDNA. Results:...
<b><i>Introduction:</i></b> High-grade lung neuroendocrine tumours with carcinoid morphology have been recently reported; they may represent the thoracic counterparts of grade 3 digestive tumours. We aimed to study their genetic landscape including analysis tumoral heterogeneity. <b><i>Methods:</i></b> Eleven patients high-grade (&#x3e;20% Ki-67 and/or &#x3e;10 mitoses) a were included. analysed copy number variations, somatic...
Primitive lung cancers developed on fibroses are both diagnostic and therapeutic challenges. Their incidence may increase with new more efficient fibrosis treatments. Our aim was to describe a cohort of associated idiopathic pulmonary (IPF) other fibrotic disorders (non-IPF), characterize their molecular alterations using immunohistochemistry next-generation sequencing (NGS).Thirty-one cancer samples were collected from 2001 2016 in two French reference centers for - 18 IPF group 13 non-IPF...
KIT is a tyrosine kinase receptor expressed by several tumours, which has for specific ligand the stem cell factor (SCF). main oncogene in gastrointestinal stromal tumours (GISTs), and gain-of-function mutations are present 70% of these tumours. The aim study was to measure investigate mechanisms activation 80 KIT-positive GIST patients. quantified detecting phosphotyrosine residues Western blotting. SCF production determined reverse transcriptase–PCR, ELISA and/or immunohistochemistry....
Malignant peripheral nerve sheath tumours (MPNSTs) are highly malignant and resistant. Transformation might implicate up regulation of epidermal growth factor receptor (EGFR). Fifty-two MPNST samples were studied for EGFR, Ki-67, p53, survivin expression by immunohistochemistry EGFR amplification in situ hybridization. Results correlated with clinical data. RNA was also quantified RT-PCR 20 other MPNSTs 14 dermal neurofibromas. Half the patients had a neurofibromatosis type 1 (NF1)....
Identifying molecular factors of sensitivity and resistance cancer cells to enzastaurin, a drug inhibiting protein kinase C (PKC) beta, remains major challenge improve its clinical development. Investigating the cellular effects enzastaurin in panel 20 human cell lines, we found that most displaying oncogenic K-Ras mutations also display enzastaurin. Wild-type (WT) high expressed mRNA levels epithelial markers, such as E-cadherin (CDH1), low expressions mesenchymal vimentin, N-cadherin...
Molecular and genetic investigations in endometrial carcinogenesis may have prognostic therapeutic implications. We studied the expression of EGFR, c-Met, PTEN mTOR signalling pathway (phospho-AKT/phospho-mTOR/phospho-RPS6) 69 consecutive tumours 16 tissue microarrays. also analysed PIK3CA, K-Ras mutations microsatellite instability (MSI). distinguished two groups: group 1 (grade 2 endometrioid cancers) 3 type II clear serous cell cancers). hypothesised that these histological groups might...
EGFR exon 20 insertions are rare genetic alterations in non-small-cell lung cancers (NSCLCs) that usually unresponsive to approved tyrosine kinase inhibitors (TKIs). In this paper, we describe the clinical characteristics, efficacy of EFGR TKIs and chemotherapy, resulting survival population. We retrospectively collected patients with (Exon20ins) from 11 French platforms paired them (1:2 ratio) classic Exon 19/21 mutation (controls). Between 2012 2017, 35 Exon20ins were included. These...
Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be cancer, but data missing. We aimed study the epidemiology and phenotype of cancer in an international cohort SRG variant carriers.
Abstract Background Choroidal metastases are the most common eye metastatic site. The prevalence of choroidal in NSCLC patients has been reported to vary from 0.2 7% historical series. Although previously reported, little is known about metastasis Epidermal Growth Factor Receptor (EGFR)-mutant Non-small cell lung cancer (NSCLC). This study sought describe among with EGFR-mutated and their characteristics, estimate impact on prognosis. Methods We conducted a single-center retrospective...
<b><i>ERBB4</i> fusion is a rare, novel oncogenic event involved in the development of lung adenocarcinoma that not routinely looked for, although <i>ERBB4</i> potential target for existing pan-ErbB tyrosine kinase and must be implemented laboratory</b>https://bit.ly/3nYmGQ9
Anaplastic lymphoma kinase (ALK) rearrangement is reported in 3% to 8% of patients with lung adenocarcinoma and can be detected by fluorescent situ hybridization (FISH) or indirectly immunohistochemistry. In FISH assay, isolated 5' signal (loss 3' signal) usually considered negative. We report three young nonsmoking stage IV adenocarcinoma. Strong ALK expression tumor cells immunohistochemistry was observed all cases, but revealed an pattern. Massive parallel "next-generation" sequencing...